Multi-center, Prospective, Non-interventional, Observational Study on the Efficacy and Safety of Mirabek in Adult Patients with Overactive Bladder

Overview

Journal Investig Clin Urol

Date 2025 Jan 10

PMID 39791582

Authors

Jee Soo Park

Won Sik Jang

Jongchan Kim

Moon-Hwa Park

Won Sik Ham

Affiliations

Soon will be listed here.

Abstract

Purpose: Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek) in adults diagnosed with OAB through a multicenter, prospective, non-interventional observational study.

Materials And Methods: Adult patients with OAB prescribed Mirabek SR Tab. 50 mg for the first time were recruited from hospitals between September 2021 and September 2022. Participants underwent baseline registration followed by two follow-ups at 4- and 8-week intervals. Data on demographics, medical history, OAB symptoms, vital signs, medication administration, and adverse events were collected.

Results: Among 1,714 patients, Mirabek SR Tab. 50 mg effectively improved OAB symptoms over an 8-week treatment period, with significant differences in symptom improvement between baseline and both 4- and 8-week time points as well as between 4 weeks and 8 weeks. The incidence rate of adverse events was 0.70%; most cases were mild with no severe reactions.

Conclusions: This study demonstrated that Mirabek, a generic drug of betmiga, is an effective and safe treatment option for adults with OAB. Furthermore, the introduction of generic drug reduced the costs of prescription drugs and expanded the opportunity for many patients to access mirabegron.

References

Mullen G, Kaplan S . Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia. Curr Urol Rep. 2021; 22(1):5. DOI: 10.1007/s11934-020-01017-7. View

Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin G, Mori K, Quhal F . Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2021; 8(4):1072-1089. DOI: 10.1016/j.euf.2021.08.011. View

Wagg A, Franks B, Ramos B, Berner T . Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J. 2015; 9(9-10):343-50. PMC: 4662398. DOI: 10.5489/cuaj.3098. View

Park J, Choi S, Jang W, Kim J, Ham W . Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study. Eur Urol Focus. 2024; 10(2):306-314. DOI: 10.1016/j.euf.2024.02.002. View

Ito H, Matsuo T, Mitsunari K, Ohba K, Miyata Y . Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder. Medicina (Kaunas). 2022; 58(6). PMC: 9228850. DOI: 10.3390/medicina58060825. View

Shaya F, Blume S, Gu A, Zyczynski T, Jumadilova Z . Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care. 2005; 11(4 Suppl):S121-9. View

Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K . What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2004; 14(5):341-8. DOI: 10.1002/pds.1055. View

Chapple C, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N . Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Eur Urol. 2019; 77(1):119-128. DOI: 10.1016/j.eururo.2019.09.024. View

Lightner D, Gomelsky A, Souter L, Vasavada S . Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019; 202(3):558-563. DOI: 10.1097/JU.0000000000000309. View

10.

Biers S, Reynard J, Brading A . The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006; 98(6):1310-4. DOI: 10.1111/j.1464-410X.2006.06564.x. View

11.

Schena G, Caplan M . Everything You Always Wanted to Know about β-AR * (* But Were Afraid to Ask). Cells. 2019; 8(4). PMC: 6523418. DOI: 10.3390/cells8040357. View

12.

Gray S, Anderson M, Dublin S, Hanlon J, Hubbard R, Walker R . Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015; 175(3):401-7. PMC: 4358759. DOI: 10.1001/jamainternmed.2014.7663. View

13.

Shrank W, Cox E, Fischer M, Mehta J, Choudhry N . Patients' perceptions of generic medications. Health Aff (Millwood). 2009; 28(2):546-56. PMC: 2748784. DOI: 10.1377/hlthaff.28.2.546. View

14.

Grabowski H, Long G, Mortimer R . Recent trends in brand-name and generic drug competition. J Med Econ. 2013; 17(3):207-14. DOI: 10.3111/13696998.2013.873723. View

15.

Gormley E, Lightner D, Burgio K, Chai T, Clemens J, Culkin D . Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012; 188(6 Suppl):2455-63. DOI: 10.1016/j.juro.2012.09.079. View

16.

Maman K, Aballea S, Nazir J, Desroziers K, Neine M, Siddiqui E . Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2013; 65(4):755-65. DOI: 10.1016/j.eururo.2013.11.010. View

17.

Irwin D, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S . Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6):1306-14. DOI: 10.1016/j.eururo.2006.09.019. View

18.

Nitti V, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo J . Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013; 67(7):619-32. PMC: 3752932. DOI: 10.1111/ijcp.12194. View

19.

Kesselheim A, Avorn J, Sarpatwari A . The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016; 316(8):858-71. DOI: 10.1001/jama.2016.11237. View

20.

Chapple C, Cardozo L, Nitti V, Siddiqui E, Michel M . Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2013; 33(1):17-30. DOI: 10.1002/nau.22505. View